The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cynosure's revenues will grow 15.8% and EPS will wither -15.0%.
The average estimate for revenue is $45.8 million. On the bottom line, the average EPS estimate is $0.17.
Last quarter, Cynosure tallied revenue of $40.7 million. GAAP reported sales were 19% higher than the prior-year quarter's $34.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.07. GAAP EPS of $0.07 for Q1 were 17% higher than the prior-year quarter's $0.06 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 58.2%, 110 basis points better than the prior-year quarter. Operating margin was 7.6%, 510 basis points better than the prior-year quarter. Net margin was 3.0%, 60 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $220.4 million. The average EPS estimate is $0.68.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 368 members out of 383 rating the stock outperform, and 15 members rating it underperform. Among 89 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 81 give Cynosure a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $35.60.
Is Cynosure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.